Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Journal für Endokrinologie, Diabetologie und Stoffwechsel
Erschienen in:

15.03.2024 | Originalien

Aldosteron und Niere – eine komplexe Interaktion

verfasst von: Dr. Christoph Schwarz, Prof. PD Dr. Gregor Lindner

Erschienen in: Journal für Endokrinologie, Diabetologie und Stoffwechsel | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aldosteron ist ein Hormon mit dualer Wirkung auf die Niere. Es ist einerseits Teil eines Regulationssystems zur Aufrechterhaltung des Natrium(= Volumen‑)Haushalts, andererseits ist es für die Stabilität des Kaliumhaushalts und des Säure-Basenhaushalts mitverantwortlich. Störungen des Aldosteronsystems kennzeichnen sich deshalb durch verminderten oder erhöhten S‑Kaliumspiegel bzw. Hypo- oder Hypertonie. Aldosteron wirkt am sogenannten Aldosteron-sensitiven Abschnitt des distalen Tubulus des Nephrons, wo es verschiedene Ionentransporter aktiviert, welche die Natriumresorption und die Kaliumsekretion fördern. Schwieriger zu verstehen ist, dass eine erhöhte Aldosteronaktivität nicht immer zu einer Hypokaliämie führt (Aldosteronparadoxon) und dass Störungen von (Aldosteron-abhängigen) Ionentransportern im distalen Tubulus der Niere zu scheinbar paradoxen Situationen führen, in denen das Ausmaß der Aldosteronsekretion in der Nebenniere nicht mit der zu erwartenden Aldosteronwirkung übereinstimmt (Pseudo-Hypo‑/Hyperaldosteronismus). Dahinter können sich seltene monogenetische Erkrankungen, aber auch erworbene Ursachen verbergen. Anhand von drei Fallbeispielen werden die wesentlichen Interaktionen zwischen Aldosteron und dem distalen Tubulusabschnitt der Niere erklärt.
Vorheriger Artikel Editorial
Nächster Artikel Auswirkungen einer Ernährungs‑, Sport- und Lifestyleintervention auf die Gesundheitsparameter von Volksschulkindern: das EDDY-Kids-Projekt 2019
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Buffolo F, Tetti M, Mulatero P, Monticone S (2022) Aldosterone as a mediator of cardiovascular damage. Hypertens 79:1899–1911
2.
Rossier BC, Baker ME, Studer RA (2015) Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol Rev 95:297–340PubMed
3.
Oliver WJ, Cohen EL, Neel JV (1975) Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a ‘no-salt’ culture. Circulation 52:146–151PubMed
4.
Escoubet B et al (2013) Cardiovascular effects of aldosterone: insight from adult carriers of mineralocorticoid receptor mutations. Circ Cardiovasc Genet 6:381–390PubMed
5.
6.
Ayuzawa N, Fujita T (2021) The mineralocorticoid receptor in salt-sensitive hypertension and renal injury. J Am Soc Nephrol 32:279–289PubMedPubMedCentral
7.
Nishimoto M et al (2019) Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res 42:514–521PubMed
8.
Nogueira EF, Xing Y, Morris CAV, Rainey WE (2009) Role of angiotensin II-induced rapid response genes in the regulation of enzymes needed for aldosterone synthesis. J Mol Endocrinol 42:319–330PubMedPubMedCentral
9.
Bandulik S, Tauber P, Lalli E, Barhanin J, Warth R (2015) Two-pore domain potassium channels in the adrenal cortex. Pflugers Arch 467:1027–1042PubMed
10.
Epstein M, Kovesdy CP, Clase CM, Sood MM, Pecoits-Filho R (2022) Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms. Am J Kidney Dis 80:658–666PubMed
11.
Palmer BF, Clegg DJ (2022) Extrarenal effects of aldosterone on potassium homeostasis. Kidney360 3:561–568PubMedPubMedCentral
12.
Funder JW, Pearce PT, Smith R, Smith AI (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583–585PubMed
13.
Shibata S et al (2013) Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab 18:660–671PubMedPubMedCentral
14.
Gallafassi EA, Bezerra MB, Rebouças NA (2023) Control of sodium and potassium homeostasis by renal distal convoluted tubules. Braz J Med Biol Res 56:e12392PubMedPubMedCentral
15.
Funder JW (2013) Angiotensin retains sodium by dephosphorylating mineralocorticoid receptors in renal intercalated cells. Cell Metab 18:609–610PubMed
16.
Pech V et al (2015) Pendrin gene ablation alters ENaC subcellular distribution and open probability. Am J Physiol Renal Physiol 309:F154–F163PubMedPubMedCentral
17.
Winter C et al (2011) Aldosterone stimulates vacuolar H(+)-ATPase activity in renal acid-secretory intercalated cells mainly via a protein kinase C‑dependent pathway. Am J Physiol Cell Physiol 301:C1251–C1261PubMedPubMedCentral
18.
Kristensen M, Fenton RA, Poulsen SB (2022) Dissecting the effects of Aldosterone and hypokalemia on the epithelial na+ channel and the nacl cotransporter. Front Physiol 13:800055PubMedPubMedCentral
19.
Cheng L et al (2019) Rapid Aldosterone-mediated signaling in the DCT increases activity of the Thiazide-sensitive NaCl cotransporter. J Am Soc Nephrol 30:1454–1470PubMedPubMedCentral
20.
Arroyo JP, Ronzaud C, Lagnaz D, Staub O, Gamba G (2011) Aldosterone paradox: differential regulation of ion transport in distal nephron. Physiology 26:115–123PubMed
21.
Hoorn EJ, Gritter M, Cuevas CA, Fenton RA (2020) Regulation of the Renal NaCl cotransporter and Its role in potassium homeostasis. Physiol Rev 100:321–356PubMed
22.
McDonough AA, Fenton RA (2022) Potassium homeostasis: sensors, mediators, and targets. Pflugers Arch 474:853–867PubMedPubMedCentral
23.
Pearce D, Manis AD, Nesterov V, Korbmacher C (2022) Regulation of distal tubule sodium transport: mechanisms and roles in homeostasis and pathophysiology. Pflugers Arch 474:869–884PubMedPubMedCentral
24.
Thomson SC, Blantz RC (2008) Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis. J Am Soc Nephrol 19:2272–2275PubMed
25.
Bassett MH, White PC, Rainey WE (2004) The regulation of aldosterone synthase expression. Mol Cell Endocrinol 217:67–74PubMed
26.
Gonzalez-Villalobos RA et al (2013) The absence of intrarenal ACE protects against hypertension. J Clin Invest 123:2011–2023PubMedPubMedCentral
27.
Saccomani G, Mitchell KD, Navar LG (1990) Angiotensin II stimulation of Na(+)-H+ exchange in proximal tubule cells. Am J Physiol 258:F1188–F1195PubMed
28.
Castañeda-Bueno M et al (2017) Phosphorylation by PKC and PKA regulate the kinase activity and downstream signaling of WNK4. Proc Natl Acad Sci U S A 114:E879–E886PubMedPubMedCentral
29.
van der Lubbe N et al (2011) Angiotensin II induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter independent of aldosterone. Kidney Int 79:66–76PubMed
30.
Hirohama D et al (2018) Aldosterone is essential for Angiotensin II-induced upregulation of Pendrin. J Am Soc Nephrol 29:57–68PubMed
31.
Nesterov V et al (2021) Critical role of the mineralocorticoid receptor in aldosterone-dependent and aldosterone-independent regulation of ENaC in the distal nephron. Am J Physiol Renal Physiol 321:F257–F268PubMedPubMedCentral
32.
Maeoka Y et al (2022) Mineralocorticoid receptor antagonists cause natriuresis in the absence of Aldosterone. Hypertens 79:1423–1434
33.
Wu P et al (2020) Effect of Angiotensin II on ENaC in the distal convoluted tubule and in the cortical collecting duct of mineralocorticoid receptor deficient mice. J Am Heart Assoc 9:e14996PubMedPubMedCentral
34.
Yue P et al (2011) Angiotensin II diminishes the effect of SGK1 on the WNK4-mediated inhibition of ROMK1 channels. Kidney Int 79:423–431PubMed
35.
Gong Y, Hou J (2017) Claudins in barrier and transport function—the kidney. Pflugers Arch 469:105–113PubMed
36.
Le Moellic C et al (2005) Aldosterone and tight junctions: modulation of claudin‑4 phosphorylation in renal collecting duct cells. Am J Physiol, Cell Physiol 289:C1513–C1521PubMed
37.
Sassi A et al (2020) Interaction between epithelial sodium channel γ‑subunit and Claudin‑8 modulates paracellular sodium permeability in renal collecting duct. J Am Soc Nephrol Jasn 31:1009–1023PubMed
38.
Shibata S (2019) Role of Pendrin in the pathophysiology of Aldosterone-induced hypertension. Am J Hypertens 32:607–613PubMed
39.
Leviel F et al (2010) The Na+-dependent chloride-bicarbonate exchanger SLC4A8 mediates an electroneutral Na+ reabsorption process in the renal cortical collecting ducts of mice. J Clin Invest 120:1627–1635PubMedPubMedCentral
40.
Ganong WF, Mulrow PJ (1958) Rate of change in sodium and potassium excretion after injection of aldosterone into the aorta and renal artery of the dog. Am J Physiol 195:337–342PubMed
41.
Velarde-Miranda C, Gomez-Sanchez EP, Gomez-Sanchez CE (2013) Regulation of aldosterone biosynthesis by the Kir3.4 (KCNJ5) potassium channel. Clin Exp Pharmacol Physiol 40:895–901PubMed
42.
Guagliardo NA et al (2019) Adrenal tissue-specific deletion of TASK channels causes Aldosterone-driven Angiotensin II-independent hypertension. Hypertens 73:407–414
43.
Rengarajan S et al (2014) Increasing plasma [K+] by intravenous potassium infusion reduces NCC phosphorylation and drives kaliuresis and natriuresis. Am J Physiol Renal Physiol 306:F1059–F1068PubMedPubMedCentral
44.
Sorensen MV et al (2013) Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in mice. Kidney Int 83:811–824PubMed
45.
Bazúa-Valenti S et al (2015) The effect of WNK4 on the na+-cl− cotransporter is modulated by intracellular chloride. J Am Soc Nephrol 26:1781–1786PubMed
46.
Pleinis JM et al (2021) WNKs are potassium-sensitive kinases. Am J Physiol, Cell Physiol 320:C703–C721PubMed
47.
Grimm PR et al (2023) Dietary potassium stimulates Ppp1Ca-Ppp1r1a dephosphorylation of kidney NaCl cotransporter and reduces blood pressure. J Clin Invest 133:e158498PubMedPubMedCentral
48.
Nesterov V, Bertog M, Korbmacher C (2022) High baseline ROMK activity in the mouse late distal convoluted and early connecting tubule probably contributes to aldosterone-independent K+ secretion. Am J Physiol Renal Physiol 322:F42–F54PubMed
49.
Todkar A et al (2015) Mechanisms of renal control of potassium homeostasis in complete aldosterone deficiency. J Am Soc Nephrol 26:425–438PubMed
50.
Wade JB et al (2011) Differential regulation of ROMK (Kir1.1) in distal nephron segments by dietary potassium. Am J Physiol Ren Physiol 300:F1385–F1393
51.
Saha B et al (2023) Potassium activates mTORC2-dependent SGK1 phosphorylation to stimulate epithelial sodium channel: role in rapid renal responses to dietary potassium. J Am Soc Nephrol 34:1019–1038PubMedPubMedCentral
52.
Yang L et al (2021) ENaC and ROMK channels in the connecting tubule regulate renal K+ secretion. J Gen Physiol 153:e202112902PubMedPubMedCentral
53.
Wald H, Garty H, Palmer LG, Popovtzer MM (1998) Differential regulation of ROMK expression in kidney cortex and medulla by aldosterone and potassium. Am J Physiol 275:F239–F245PubMed
54.
Cornelius RJ et al (2015) Low Na, high K diet and the role of aldosterone in BK-mediated K excretion. PLoS ONE 10:e115515PubMedPubMedCentral
55.
Mamenko MV et al (2017) The renal TRPV4 channel is essential for adaptation to increased dietary potassium. Kidney Int 91:1398–1409PubMedPubMedCentral
56.
Stavniichuk A et al (2023) TRPV4 expression in the renal tubule is necessary for maintaining whole body K+ homeostasis. Am J Physiol Renal Physiol 324:F603–F616PubMedPubMedCentral
57.
van Buren M, Rabelink AJ, Bijlsma JA, Koomans HA (1993) Natriuretic and kaliuretic response to potassium load: modulation by sodium intake. Nephrol Dial Transplant 8:495–500PubMed
58.
Kamel KS, Schreiber M, Halperin ML (2018) Renal potassium physiology: integration of the renal response to dietary potassium depletion. Kidney Int 93:41–53PubMed
59.
Young DB, Paulsen AW (1983) Interrelated effects of aldosterone and plasma potassium on potassium excretion. Am J Physiol 244:F28–F34PubMed
60.
Thomson MN et al (2020) WNK bodies cluster WNK4 and SPAK/OSR1 to promote NCC activation in hypokalemia. Am J Physiol Renal Physiol 318:F216–F228PubMed
61.
Wang M‑X et al (2018) Potassium intake modulates the thiazide-sensitive sodium-chloride cotransporter (NCC) activity via the Kir4.1 potassium channel. Kidney Int 93:893–902PubMedPubMedCentral
62.
Murillo-de-Ozores AR et al (2022) Multiple molecular mechanisms are involved in the activation of the kidney sodium-chloride cotransporter by hypokalemia. Kidney Int 102:1030–1041PubMedPubMedCentral
63.
Al-Qusairi L et al (2023) Dietary anions control potassium excretion: it is more than a poorly absorbable anion effect. Am J Physiol Renal Physiol 325:F377–F393PubMed
64.
Wei Y, Zavilowitz B, Satlin LM, Wang WH (2007) Angiotensin II inhibits the ROMK-like small conductance K channel in renal cortical collecting duct during dietary potassium restriction. J Biol Chem 282:6455–6462PubMed
65.
Elabida B et al (2011) Chronic potassium depletion increases adrenal progesterone production that is necessary for efficient renal retention of potassium. Kidney Int 80:256–262PubMed
66.
Blanchard A et al (2020) Adrenal adaptation in potassium-depleted men: role of progesterone? Nephrol Dial Transplant 35:1901–1908PubMed
67.
Gumz ML, Lynch IJ, Greenlee MM, Cain BD, Wingo CS (2010) The renal H+-K+-ATPases: physiology, regulation, and structure. Am J Physiol Renal Physiol 298:F12–F21PubMed
68.
Lasaad S et al (2023) GDF15 mediates renal cell plasticity in response to potassium depletion in mice. Acta Physiol 239:e14046
69.
Pham TD et al (2022) Pendrin-null mice develop severe hypokalemia following dietary Na+ and K+ restriction: role of ENaC. Am J Physiol Renal Physiol 322:F486–F497PubMedPubMedCentral
70.
Terker AS et al (2015) Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. Cell Metab 21:39–50PubMedPubMedCentral
71.
Wu A et al (2023) Randomized trial on the effect of oral potassium chloride supplementation on the thiazide-sensitive sodium chloride cotransporter in healthy adults. Kidney Int Rep 8:1201–1212PubMedPubMedCentral
72.
Xu N et al (2017) Hypokalemia and pendrin induction by aldosterone. Hypertens 69:855–862
73.
Pham TD et al (2020) Aldosterone regulates pendrin and epithelial sodium channel activity through intercalated cell mineralocorticoid receptor-dependent and -independent mechanisms over a wide range in serum potassium. J Am Soc Nephrol 31:483–499PubMedPubMedCentral
74.
Terker AS et al (2016) Direct and indirect mineralocorticoid effects determine distal salt transport. J Am Soc Nephrol 27:2436–2445PubMed
75.
Ayuzawa N et al (2020) Two mineralocorticoid receptor-mediated mechanisms of pendrin activation in distal nephrons. J Am Soc Nephrol 31:748–764PubMedPubMedCentral
76.
Ozbaki-Yagan N, Liu X, Bodnar AJ, Ho J, Butterworth MB (2020) Aldosterone-induced microRNAs act as feedback regulators of mineralocorticoid receptor signaling in kidney epithelia. FASEB J 34:11714–11728PubMed
77.
Schrier RW (2010) Aldosterone ‘escape’ vs ‘breakthrough. Nat Rev Nephrol 6:61PubMed
78.
Khandelwal P, Deinum J (2022) Monogenic forms of low-renin hypertension: clinical and molecular insights. Pediatr Nephrol 37:1495–1509PubMed
79.
Nanba K, Rainey WE (2022) Pathophysiology of bilateral hyperaldosteronism. Curr Opin Endocrinol Diabetes Obes 29:233–242PubMedPubMedCentral
80.
Meyer LS, Gong S, Reincke M, Williams TA (2020) Angiotensin II type 1 receptor autoantibodies in primary aldosteronism. Horm Metab Res 52:379–385PubMedPubMedCentral
81.
82.
Boyle RA, Baker JE, Charu V, Rainey WE, Bhalla V (2021) Masking by hypokalemia-primary aldosteronism with undetectable aldosterone. Clin Kidney J 14:1269–1271PubMed
83.
Freeman MW et al (2023) Phase 2 trial of Baxdrostat for treatment-resistant hypertension. N Engl J Med 388:395–405PubMed
84.
Grimm PR, Coleman R, Delpire E, Welling PA (2017) Constitutively active SPAK causes hyperkalemia by activating NCC and remodeling distal tubules. J Am Soc Nephrol Jasn 28:2597–2606PubMed
85.
Favre GA et al (2012) Localization of tubular adaptation to renal sodium loss in Gitelman syndrome. Clin J Am Soc Nephrol 7:472–478PubMedPubMedCentral
86.
Geller DS et al (1998) Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 19:279–281PubMed
87.
Geller DS et al (2006) Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol 17:1429–1436PubMed
88.
Riepe FG (2009) Clinical and molecular features of type 1 pseudohypoaldosteronism. Horm Res 72:1–9PubMed
89.
Bandhakavi M et al (2021) Clinical characteristics and treatment requirements of children with autosomal recessive pseudohypoaldosteronism. Eur J Endocrinol 184:K15–K20PubMed
90.
Rubera I et al (2003) Collecting duct-specific gene inactivation of alphaENaC in the mouse kidney does not impair sodium and potassium balance. J Clin Invest 112:554–565PubMedPubMedCentral
91.
Boscardin E et al (2018) Plasma potassium determines NCC abundance in adult kidney-specific γENaC knockout. J Am Soc Nephrol 29:977–990PubMedPubMedCentral
92.
Boscardin E et al (2017) Severe hyperkalemia is rescued by low-potassium diet in renal βENaC-deficient mice. Pflugers Arch 469:1387–1399PubMed
93.
Perrier R et al (2016) Severe salt-losing syndrome and Hyperkalemia induced by adult nephron-specific knockout of the epithelial sodium channel α‑subunit. J Am Soc Nephrol 27:2309–2318PubMed
94.
Kerem E et al (1999) Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 341:156–162PubMed
95.
Delforge X et al (2019) Transient pseudohypoaldosteronism: a potentially severe condition affecting infants with urinary tract malformation. J Pediatr Urol 15:265.e1–265.e7PubMed
96.
Batlle DC, Arruda JA, Kurtzman NA (1981) Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 304:373–380PubMed
97.
Zietse R, Zoutendijk R, Hoorn EJ (2009) Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 5:193–202PubMed
98.
Schaedel C et al (1999) Lung symptoms in pseudohypoaldosteronism type 1 are associated with deficiency of the alpha-subunit of the epithelial sodium channel. J Pediatr 135:739–745PubMed
99.
Ellison DH, Terker AS, Gamba G (2016) Potassium and its discontents: new insight, new treatments. J Am Soc Nephrol 27:981–989PubMed
100.
O’Shaughnessy KM (2015) Gordon Syndrome: a continuing story. Pediatr Nephrol 30:1903–1908PubMed
101.
Arroyo JP et al (2011) Nedd4‑2 modulates renal Na+- Cl− cotransporter via the aldosterone-SGK1-Nedd4‑2 pathway. J Am Soc Nephrol Jasn 22:1707–1719PubMed
102.
Faresse N et al (2012) Inducible kidney-specific Sgk1 knockout mice show a salt-losing phenotype. Am J Physiol Renal Physiol 302:F977–F985PubMed
103.
Picard N et al (2014) Protein phosphatase 1 inhibitor‑1 deficiency reduces phosphorylation of renal NaCl cotransporter and causes arterial hypotension. J Am Soc Nephrol 25:511–522PubMed
104.
Adachi M et al (2023) Classification of pseudohypoaldosteronism type II as type IV renal tubular acidosis: results of a literature review. Endocr J 70:723–729PubMed
105.
López-Cayuqueo KI et al (2018) A mouse model of pseudohypoaldosteronism type II reveals a novel mechanism of renal tubular acidosis. Kidney Int 94:514–523PubMed
106.
Yamauchi K et al (2004) Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci U S A 101:4690–4694PubMedPubMedCentral
107.
Healy JK (2014) Pseudohypoaldosteronism Type II. Hypertension 63:648–654PubMed
108.
Hoorn EJ et al (2011) The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 17:1304–1309PubMedPubMedCentral
109.
Gao Z‑X et al (2023) Activation of Kir4.1/Kir5.1 contributes to the cyclosporin A‑induced stimulation of the renal NaCl cotransporter and hyperkalemic hypertension. Acta Physiol 238:e13948
110.
Ishizawa K et al (2019) Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling. Proc Natl Acad Sci U S A 116:3155–3160PubMedPubMedCentral
111.
Shoda W et al (2017) Calcineurin inhibitors block sodium-chloride cotransporter dephosphorylation in response to high potassium intake. Kidney Int 91:402–411PubMed
112.
An C, Liang J, Zhang K, Su X (2016) Polymorphisms in the SLC12A3 gene encoding sodium-chloride cotransporter are associated with hypertension: a family-based study in the Mongolian population. Kidney Blood Press Res 41:18–28PubMed
113.
Erger F (2018) Monogene Formen der arteriellen Hypertonie. Med Genet 30:391–399
114.
Rizzolo K, Beck NM, Ambruso SL (2022) Syndromes of pseudo-hyperaldosteronism. Clin J Am Soc Nephrol 17:581–584PubMedPubMedCentral
115.
Shimkets RA et al (1994) Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79:407–414PubMed
116.
Hansson JH et al (1995) Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 11:76–82PubMed
117.
Rossier BC, Schild L (2008) Epithelial sodium channel: mendelian versus essential hypertension. Hypertens 52:595–600
118.
Salih M et al (2017) A missense mutation in the extracellular domain of αENaC causes Liddle syndrome. J Am Soc Nephrol 28:3291–3299PubMedPubMedCentral
119.
Ronzaud C et al (2013) Renal tubular NEDD4‑2 deficiency causes NCC-mediated salt-dependent hypertension. J Clin Invest 123:657–665PubMedPubMedCentral
120.
Warnock DG (2001) Liddle syndrome: genetics and mechanisms of Na+ channel defects. Am J Med Sci 322:302–307PubMed
121.
Bohnert BN et al (2021) Experimental nephrotic syndrome leads to proteolytic activation of the epithelial Na+ channel in the mouse kidney. Am J Physiol Ren Physiol 321:F480–F493
122.
Essigke D et al (2022) Sodium retention in nephrotic syndrome is independent of the activation of the membrane-anchored serine protease prostasin (CAP1/PRSS8) and its enzymatic activity. Pflugers Arch 474:613–624PubMedPubMedCentral
123.
Artunc F et al (2022) Proteolytic activation of the epithelial sodium channel (ENaC) by factor VII activating protease (FSAP) and its relevance for sodium retention in nephrotic mice. Pflugers Arch 474:217–229PubMed
124.
Geller DS et al (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119–123PubMed
125.
Hindosh N, Hindosh R, Dada B, Bal S (2022) Geller syndrome: a rare cause of persistent hypokalemia during pregnancy. Cureus 14:e26272PubMedPubMedCentral
126.
Zennaro M‑C, Fernandes-Rosa F (2017) 30 years of the mineralocorticoid receptor: mineralocorticoid receptor mutations. J Endocrinol 234:T93–T106PubMed
127.
Hunter RW et al (2015) Hypertrophy in the distal convoluted tubule of an 11β-Hydroxysteroid dehydrogenase type 2 knockout model. J Am Soc Nephrol 26:1537–1548PubMed
128.
Yau M et al (2017) Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency. Proc Natl Acad Sci U S A 114:E11248–E11256PubMedPubMedCentral
129.
Ueda K et al (2017) Renal dysfunction induced by kidney-specific gene deletion of Hsd11b2 as a primary cause of salt-dependent hypertension. Hypertens 70:111–118
130.
131.
Kuriakose K, Nesbitt WJ, Greene M, Harris B (2018) Posaconazole-induced pseudohyperaldosteronism. Antimicrob Agents Chemother 62:e2130–17PubMedPubMedCentral
132.
Brandi SL, Feltoft CL, Serup J, Eldrup E (2021) Pseudohyperaldosteroism during itraconazole treatment: a hitherto neglected clinically significant side effect. BMJ Case Rep 14:e243191PubMedPubMedCentral
133.
Dötsch J, Dörr HG, Stalla GK, Sippell WG (2001) Effect of glucocorticoid excess on the cortisol/cortisone ratio. Steroids 66:817–820PubMed
134.
Vitellius G, Lombes M (2020) Genetics in endocrinology: glucocorticoid resistance syndrome. Eur J Endocrinol 182:R15–R27PubMed
135.
Claahsen-van der Grinten HL et al (2022) Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev 43:91–159PubMed
136.
Bulsari K, Falhammar H (2017) Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Endocrine 55:19–36PubMed
137.
138.
Sun M et al (2021) The broad phenotypic spectrum of 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency: a case series. Eur J Endocrinol 185:729–741PubMedPubMedCentral
139.
Zhou Y, Xue X, Shi P, Lu Q, Lv S (2021) Multidisciplinary team management of 46,XY 17α-hydroxylase deficiency: a case report and literature review. J Int Med Res 49:300060521993965PubMed
140.
Schwab KO, Moisan A‑M, Homoki J, Peter M, Simard J (2005) 17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister. J Pediatr Endocrinol Metab 18:403–411PubMed
141.
Bockenhauer D, Kleta R (2021) Tubulopathy meets Sherlock Holmes: biochemical fingerprinting of disorders of altered kidney tubular salt handling. Pediatr Nephrol 36:2553–2561PubMedPubMedCentral
142.
Reichold M et al (2010) KCNJ10 gene mutations causing EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) disrupt channel function. Proc Natl Acad Sci U S A 107:14490–14495PubMedPubMedCentral
143.
Scholl UI et al (2009) Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci U S A 106:5842–5847PubMedPubMedCentral
144.
Schlingmann KP et al (2021) Defects in KCNJ16 cause a novel tubulopathy with hypokalemia, salt wasting, disturbed acid-base homeostasis, and sensorineural deafness. J Am Soc Nephrol 32:1498–1512PubMedPubMedCentral
145.
Wang W‑H, Lin D‑H (2022) Inwardly rectifying K+ channels 4.1 and 5.1 (Kir4.1/Kir5.1) in the renal distal nephron. Am J Physiol Cell Physiol 323:C277–C288PubMedPubMedCentral
146.
Lo J, Forst A‑L, Warth R, Zdebik AA (2022) EAST/SeSAME syndrome and beyond: the spectrum of Kir4.1- and Kir5.1-associated channelopathies. Front Physiol 13:852674PubMedPubMedCentral
147.
Seys E et al (2017) Clinical and genetic spectrum of Bartter syndrome type 3. J Am Soc Nephrol 28:2540–2552PubMedPubMedCentral
148.
Schlingmann KP, de Baaij JHF (2022) The genetic spectrum of Gitelman(-like) syndromes. Curr Opin Nephrol Hypertens 31:508–515PubMedPubMedCentral
149.
Loffing J et al (2004) Altered renal distal tubule structure and renal Na(+) and Ca(2+) handling in a mouse model for Gitelman’s syndrome. J Am Soc Nephrol Jasn 15:2276–2288PubMed
150.
Eder M et al (2020) Markers of potassium homeostasis in salt losing tubulopathies-associations with hyperaldosteronism and hypomagnesemia. BMC Nephrol 21:256PubMedPubMedCentral
151.
Patel-Chamberlin M et al (2016) The role of epithelial sodium channel ENaC and the apical cl−/HCO3−exchanger pendrin in compensatory salt reabsorption in the setting of na-cl Cotransporter (NCC) inactivation. PLoS ONE 11:e150918PubMedPubMedCentral
152.
Soleimani M et al (2012) Double knockout of pendrin and Na-Cl cotransporter (NCC) causes severe salt wasting, volume depletion, and renal failure. Proc Natl Acad Sci U S A 109:13368–13373PubMedPubMedCentral
153.
Seyberth HW (2008) An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 4:560–567PubMed
154.
Dimke H et al (2013) Activation of the Ca(2+)-sensing receptor increases renal claudin-14 expression and urinary Ca(2+) excretion. Am J Physiol Renal Physiol 304:F761–F769PubMed
155.
Vargas-Poussou R et al (2002) Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 13:2259–2266PubMed
156.
Metadaten
Titel
Aldosteron und Niere – eine komplexe Interaktion
verfasst von
Dr. Christoph Schwarz
Prof. PD Dr. Gregor Lindner
Publikationsdatum
15.03.2024
Verlag
Springer Vienna
Erschienen in
Journal für Endokrinologie, Diabetologie und Stoffwechsel / Ausgabe 2/2024
Print ISSN: 3004-8915
Elektronische ISSN: 3004-8923
DOI
https://doi.org/10.1007/s41969-024-00224-8

Weitere Artikel der Ausgabe 2/2024

Metabolisches Syndrom in Schach halten heißt auch Krebs vermeiden

  • Aktuell

Auswirkungen einer Ernährungs‑, Sport- und Lifestyleintervention auf die Gesundheitsparameter von Volksschulkindern: das EDDY-Kids-Projekt 2019

  • Originalien

Mit Inkretinmimetika deutliche Gewichtsreduktion auch bei Typ-1-Diabetes

  • Aktuell

Wie das Kunststoffzeitalter unsere Hormone beeinträchtigt

  • Aktuell

Neues zum Hypophysenhinterlappen

  • Open Access
  • Originalien

Hyperthyreose: Schilddrüsen-Op. senkt Herzinfarktrisiko

  • Aktuell